Drug intelligence / Profile preview

bromfenac

Development stage: Approved
Lead developer: General Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

Acunac is a brand name for bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) developed by Pharmaceutical General. It is typically formulated as an ophthalmic solution. Bromfenac works by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which prevents the synthesis of prostaglandins that mediate inflammation and pain. It is primarily indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery.

Brand names: Acunac
Other names: bromfenac sodium

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on bromfenac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromfenac.

Explore the full profile